Is Recursion Pharmaceuticals Stock a Buy?
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
Trending Industry Today: Recursion Pharmaceuticals Leads Gains In NVIDIA Holdings Stocks
July 12th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending up in regular trading hours with 4 constituents up and Recursion Pharmaceuticals leading Gains.$Recursion Pharmaceuticals(RXRX.
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $12
KeyBanc analyst Scott Schoenhaus maintains $Recursion Pharmaceuticals(RXRX.US)$ with a buy rating, and adjusts the target price from $16 to $12.According to TipRanks data, the analyst has a success
Express News | Keybanc Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $12
Recursion Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 65.52% Keybanc $16 → $12 Maintains Overweight 06/25/2024 134.48% Needham $17 → $17 Reiterates
Form 144 | Recursion Pharmaceuticals(RXRX.US) Officer Proposes to Sell 108.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Recursion Pharmaceuticals(RXRX.US)$ Officer Secora Michael intends to sell 15,000 shares of its common stock on Jul 10, with a total market value of approximately $108
Form 144 | Recursion Pharmaceuticals(RXRX.US) Officer Proposes to Sell 374K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Recursion Pharmaceuticals(RXRX.US)$ Officer Gibson Christopher intends to sell 50,000 shares of its common stock on Jul 10, with a total market value of
Form 144 | Recursion Pharmaceuticals(RXRX.US) Officer Proposes to Sell 109.78K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 9, $Recursion Pharmaceuticals(RXRX.US)$ Officer Secora Michael intends to sell 15,000 shares of its common stock on Jul 9, with a total market value of approximately $109.7
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
07:41 AM EDT, 07/09/2024 (MT Newswires) -- Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price TargetPrice: 7.46, Change: +0.06, Percent Change: +0.81
Trending Industry Today: Arm Holdings Leads Gains In NVIDIA Holdings Stocks
July 5th - The industry of $NVIDIA Holdings(LIST20882.US)$ is trending up in regular trading hours with 2 constituents up, 2 constituents down and Arm Holdings leading Gains.$Arm Holdings(ARM.US)$ up
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.
Recursion Pharmaceuticals(RXRX.US) Officer Sells US$43,290 in Common Stock
$Recursion Pharmaceuticals(RXRX.US)$ Officer Marriott Tina sold 6,000 shares of common stock on Jun 27, 2024 at an average price of $7.215 for a total value of $43,290.Source: Announcement What is sta
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
Express News | Recursion Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $9 From $10
Recursion Pharmaceuticals(RXRX.US) Director Sells US$108.81K in Common Stock
$Recursion Pharmaceuticals(RXRX.US)$ Director Borgeson Blake sold 11,447 shares of common stock on Jun 25, 2024 at an average price of $9.5052 for a total value of $108.81K.Source: Announcement What i
Recursion Pharmaceuticals Down Nearly 18%, on Pace for Largest Percent Decrease Since March 2022 -- Data Talk
Recursion Pharmaceuticals, Inc. Class A (RXRX) is currently at $7.18, down $1.58 or 17.98% --Would be lowest close since Dec. 5, 2023, when it closed at $7.10 --On pace for largest percent decrease
Express News | Recursion Pharmaceuticals Shares Drop 20% After Co Files for Deep-Discounted $200 Million Stock Offering